Moleculin Biotech (MBRX) Starts Presentation at LD Micro Main Event
Moleculin Biotech (NASDAQ: MBRX) is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company's lead product candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). Moleculin Biotech also has two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors. For more information, visit the company's website at www.moleculin.com. About…







